The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's ...

The GSK oncology products it has sold on to Novartis were ... Other drugs in the portfolio include Votrient, for renal cell carcinoma, Promacta for thrombocytopenia, HER2+ metastatic breast ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Bringing people together is the best way to innovate and deliver products that transform ... the vaccines of the future. GSK’s broad and far-reaching vaccine portfolio. GSK’s marketed vaccines ...

“Emma led the executive team and the wider organisation to deliver continued, improved operating performance in 2024, with GSK’s reshaped product portfolio demonstrating both strength and ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

LONDON, Feb 27 (Reuters) - British drugmaker GSK (GSK.L), opens new tab will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.